Visco-ease

Visco-ease (LMS-611) is a multi-lipid mimetic of naturally occurring lamellar bodies, developed by Lamellar Biomedical Ltd in collaboration with NHS Greater Glasgow and Clyde. Classified as a medical device or non-pharmacological agent, it is composed of natural lipids commonly found in food. The product is designed to treat radiotherapy-induced xerostomia (RIX) and the 'sticky saliva' symptom in head and neck cancer patients. Visco-ease is administered as a sublingual spray and works by modifying the rheological properties of the oral mucosa to reduce the viscosity and adhesiveness of thickened saliva. A randomized, double-blind, placebo-controlled Phase 2 trial (NCT02687087) was completed in 2017; however, the study did not meet its primary endpoint, showing no statistically significant difference from placebo in GRIX questionnaire scores.

Brand names

Visco-ease

Other names

RIX - LMS-611x-20OXB/1-20